AstraZeneca abandoned the new crown vaccine for beta variants and has entered clinical phase 2/3!

CompilationAspirin

AstraZeneca's Covid-19 vaccine for the beta variant entered Phase 2/3 of clinical trials last year

Another important reason was that there was no significant difference between the immunogenicity of AZD2816 and Vaxzevria

For these two reasons, AstraZeneca will abandon the beta variant and stick with its first-generation vaccine, Vaxzevria

When the beta variant was discovered in October 2020, it represented the most worrying variant of the new coronavirus at the time from an immune escape perspective

Given the small genetic differences between the beta variant and the original SARS-CoV-2 virus, AstraZeneca responded by tweaking its first-generation Vaxzevria vaccine

AstraZeneca dosed the first subjects in a Phase 2/3 clinical trial in June 2021

The rise and fall of AZD2816 offers a cautionary tale for Moderna and Pfizer

AstraZeneca disclosed the termination of AZD2816 in its quarterly report, while revealing the removal of a series of early-stage projects from its pipeline

Reference article: AstraZeneca dumps late-phase, next-gen COVID-19 vaccine, calling time on a beta player in an omicron world